Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CATALYST PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for CATALYST PHARMACEUTICALS, INC.

CPRX

CATALYST PHARMACEUTICALS, INC.

About CATALYST PHARMACEUTICALS, INC.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company specializing in in-licensing, developing, and commercializing treatments for rare and difficult-to-treat diseases. Its core products include FIRDAPSE® for Lambert-Eaton myasthenic syndrome, FYCOMPA® for epilepsy, and AGAMREE® for Duchenne muscular dystrophy. Catalyst targets niche patient populations through specialized sales forces, personalized patient support programs, and partnerships, focusing on orphan drug markets with strong intellectual property protections.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CATALYST PHARMACEUTICALS, INC.

1
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports $149.4 Million Revenue in Q1 2026, Driven by FIRDAPSE® and AGAMREE® Sales

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports $589M Revenue and $214.3M Net Income for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports 15.4% Revenue Growth to $148.4 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports Revenue Growth to $146.6 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports 43.4% Revenue Growth to $141.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports $491.7M Revenue and $163.9M Net Income for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports Significant Revenue Growth and Improved Financials in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments